Pfizer’s Covid story — and revenue spree — continue with $54B vaccine and pill in spotlight again
Covid, Covid and more Covid news and questioning dominated Pfizer’s financial call with investors on Tuesday — and of course, its top line revenue.
Pfizer reported sales of $25.7 billion for the first three months, driven by $13.2 billion in Comirnaty vaccine sales and $1.5 billion in Paxlovid antiviral treatments. Overall, it notched a meteoric 77% increase year over year — although excluding Comirnaty and Paxlovid from both quarters that drops to 2% operational growth.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.